iFIT Lunch & Learn Session with Prof. Dr. Birgit Schittek
Targeting signaling pathways in melanoma
On behalf of the iFIT spokespersons Lars Zender, Juliane Walz and Bernd Pichler, it is our pleasure to inform you about and invite you to the last episode of our iFIT Lunch & Learn Session 2024 that will take place
on Tuesday, December 3rd at 12:00 pm (CET)
at Big Lecture Hall in the Medizinische Klinik (Otfried-Müller-Straße 10 , 72076 Tübingen ).
Our speaker, Birgit Schittek (Department of Dermatology, Tübingen ) will give a talk on
“Targeting signaling pathways in melanoma”.
Although the development of targeted therapies that inhibit the MAPK signaling pathway has improved the prognosis of melanoma patients, melanoma remains one of the most aggressive cancers with a high mortality rate. In particular, the development of resistance to MAPK inhibitors represents a major challenge. In addition, other treatment approaches, such as immunotherapeutic therapies with immune checkpoint inhibitors, only show a durable response in about half of melanoma patients. Therefore, we urgently need to identify in melanoma key targets in activated signaling pathways to overcome treatment resistance and increase sensitivity to targeted drugs.
In my talk, I will present our work concerning the impact of inhibiting p90 ribosomal S6 kinase (RSK) as a key downstream effector of active MAPK signaling pathways on melanoma cell survival, differentiation, immunogenicity and enhancing sensitivity towards MAPK inhibitors. In addition, I will present our recent work on the efficacy of PARP inhibitors alone or in combination with MAPK inhibitors in overcoming treatment resistance and inhibiting melanoma progression.
As a special feature of this program, the iFIT will sponsor free lunch packages! (First come, first serve)
All members of the University Hospital and University of Tübingen are invited to participate!
We look forward to this Lunch & Learn Session and to see you there!
